Breaking News Instant updates and real-time market news.

VRTX

Vertex

$176.23

-0.01 (-0.01%)

13:29
10/21/19
10/21
13:29
10/21/19
13:29

Vertex says Spanish government approves national reimbursement of CF combos

Vertex Pharmaceuticals announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI and SYMKEVI in combination with KALYDECO for eligible patients in Spain living with cystic fibrosis, or CF. Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO. Ludovic Fenaux, Senior Vice President, Vertex International, commented, "Today's announcement means ORKAMBI and SYMKEVI can be prescribed from the first of November 2019 for the approximately 600 eligible cystic fibrosis patients living in Spain, to treat the underlying cause of their disease. We thank the Spanish Authorities for their collaboration and commitment to working with us in an innovative way to come to a solution for patients."

  • 19

    Mar

VRTX Vertex
$176.23

-0.01 (-0.01%)

09/03/19
GSCO
09/03/19
UPGRADE
Target $254
GSCO
Conviction Buy
Vertex upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter added Vertex Pharmaceuticals to his firm's Americas Conviction List while raising his price target for the shares to $254 from $226 and keeping a Buy rating on the name. Vertex is in the midst of a multi-year period of "rapid" margin expansion and earnings outperformance driven by growth of the legacy cystic fibrosis franchise and likely launch of VX-445 triple combination, which has a March 19 FDA action date, Richter tells investors in a research note. Further, the analyst believes investor attention should now shift to the company's emerging pipeline, where he sees a "significant opportunity" in the Phase 2-ready alpha-1 antitrypsin deficiency disorder program.
09/23/19
JEFF
09/23/19
NO CHANGE
Target $220
JEFF
Buy
Vertex price target raised to $220 from $210 at Jefferies
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $220 from $210 and reiterates a Buy rating on the shares. Potential early approval of the company's cystic fibrosis triple combo and a strong launch set up consensus to raise near-term numbers, Yee tells investors in a research note. Next year "starts to be all about the pipeline," with up to six programs that reflect $1B-$5B in potential new revenues, says the analyst. He believes Vertex "could have a big inflection in 2020-2021 as it goes from one big blockbuster to the next."
10/16/19
BOFA
10/16/19
INITIATION
Target $220
BOFA
Buy
Vertex reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Vertex with a Buy rating and $220 price target, citing the company's differentiated growth profile, upside potential in the upcoming triple combination therapy launch, and an emerging orphan disease pipeline.
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill

TODAY'S FREE FLY STORIES

NTZ

Natuzzi

$1.70

0.1 (6.25%)

17:21
11/11/19
11/11
17:21
11/11/19
17:21
Hot Stocks
Natuzzi Chief Commercial Officer Nazzario Pozzi departs »

Natuzzi announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:18
11/11/19
11/11
17:18
11/11/19
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:17
11/11/19
11/11
17:17
11/11/19
17:17
Earnings
UGI Corporation reports Q4 EPS (27c), consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

, GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

17:05
11/11/19
11/11
17:05
11/11/19
17:05
Periodicals
State AGs gather in Colorado to go over Google antitrust probe, Reuters says »

State attorneys general…

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

FB

Facebook

$189.57

-1.29 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:03
11/11/19
11/11
17:03
11/11/19
17:03
Hot Stocks
Franco-Nevada reports 133,219 Gold Equivalent Ounces sold in Q3 »

"Franco-Nevada's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:02
11/11/19
11/11
17:02
11/11/19
17:02
Earnings
Franco-Nevada reports Q3 EPS 54c, may not compare to consensus 27c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ENR

Energizer

$43.11

-0.265 (-0.61%)

16:55
11/11/19
11/11
16:55
11/11/19
16:55
Hot Stocks
Energizer appoints new CFO, Chief Legal Officer, and Chief Accounting Officer »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

16:52
11/11/19
11/11
16:52
11/11/19
16:52
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$78.70

0.22 (0.28%)

, BREW

Craft Brew

$7.33

0.06 (0.83%)

16:51
11/11/19
11/11
16:51
11/11/19
16:51
Hot Stocks
Anheuser-Busch to buy remaining Craft Brew Alliance stake for $16.50 per share »

Today, Craft Brew…

BUD

AB InBev

$78.70

0.22 (0.28%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 27

    Feb

CHAP

Chaparral Energy

$0.90

0.089 (10.99%)

16:47
11/11/19
11/11
16:47
11/11/19
16:47
Earnings
Chaparral Energy reports Q3 EPS ($2.86), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:43
11/11/19
11/11
16:43
11/11/19
16:43
Hot Stocks
DXC Technology says will pursue strategic alternatives for adjacent business »

In Q2 presentation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:41
11/11/19
11/11
16:41
11/11/19
16:41
Earnings
DXC Technology cuts FY20 EPS view to $5.25-$5.75 from $7.00-$7.75 »

Consensus $7.17. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:35
11/11/19
11/11
16:35
11/11/19
16:35
Hot Stocks
Lonestar sees Q4 production 17,200-17,600 BOE/d »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NFE

New Fortress Energy

$15.86

-0.88 (-5.26%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Earnings
New Fortress Energy reports Q3 EPS (30c), consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

TME

Tencent Music

$14.35

0.36 (2.57%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Hot Stocks
Tencent Music reports Q3 online music Mobile MAUs up 0.9% »

Reports Q3: Mobile MAU up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:33
11/11/19
11/11
16:33
11/11/19
16:33
Earnings
Lonestar has issued production guidance of 17,200 to 17,600 BOE/d for 4Q19. Prod »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FEDU

Four Seasons Education

$2.08

0.09 (4.52%)

16:33
11/11/19
11/11
16:33
11/11/19
16:33
Hot Stocks
Four Seasons Education appoints Yi Zuo CEO »

Four Seasons Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:32
11/11/19
11/11
16:32
11/11/19
16:32
Earnings
Lonestar reports Q3 EPS 33c, may not compare to consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TME

Tencent Music

$14.35

0.36 (2.57%)

16:32
11/11/19
11/11
16:32
11/11/19
16:32
Hot Stocks
Tencent Music reports Q3 online music payers up 42.2% at 35.4M »

CEO Cussion Pang says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

TME

Tencent Music

$14.35

0.36 (2.57%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
Earnings
Tencent Music reports Q3 EPS 10c, consensus 9c »

Reports Q3 revenue $910M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

KKR

KKR

$29.27

0.14 (0.48%)

, WBA

Walgreens Boots Alliance

$62.26

3.06 (5.17%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks were generally…

KKR

KKR

$29.27

0.14 (0.48%)

WBA

Walgreens Boots Alliance

$62.26

3.06 (5.17%)

EVR

Evercore Partners

$77.16

-1.14 (-1.46%)

BABA

Alibaba

$186.71

-0.4 (-0.21%)

LUV

Southwest

$58.27

0.1 (0.17%)

BA

Boeing

$366.97

16.32 (4.65%)

AAL

American Airlines

$30.58

-0.19 (-0.62%)

OTEX

OpenText

$42.54

0.99 (2.38%)

CARB

Carbonite

$22.93

4.54 (24.69%)

WE

We Company

$0.00

(0.00%)

TMUS

T-Mobile

$79.64

-1.28 (-1.58%)

S

Sprint

$5.91

-0.2 (-3.27%)

GOOG

Alphabet

$1,298.89

-10.47 (-0.80%)

GOOGL

Alphabet Class A

$1,298.21

-9.77 (-0.75%)

AAPL

Apple

$262.16

1.96 (0.75%)

AGEN

Agenus

$3.90

0.325 (9.10%)

URGN

UroGen Pharma

$24.16

0.59 (2.50%)

PLUG

Plug Power

$2.93

0.205 (7.54%)

MYOK

MyoKardia

$55.48

-4.51 (-7.52%)

SGMS

Scientific Games

$29.85

-1.74 (-5.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 22

    Nov

  • 09

    Dec

  • 12

    Dec

  • 23

    Jan

BEN

Franklin Resources

$27.95

-0.33 (-1.17%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
Hot Stocks
Franklin Resources reports preliminary AUM $693.1B as of October 31 »

Compared to $692.6B at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APYX

Apyx Medical

$7.23

0.25 (3.58%)

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Earnings
Apyx Medical raises FY19 revenue view to $27.4M-$27.9M from $26.5M-$27.5M »

Consensus $26.97M. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

RETA

Reata Pharmaceuticals

$213.50

1.46 (0.69%)

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Options
Preliminary option volume of 14.8M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.